Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ELI LILLY AND COMPANY

(LLY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Eli Lilly and : Submission of Matters to a Vote of Security Holders

05/05/2021 | 07:01am EDT
Submission of Matters to a Vote of Security Holders

Eli Lilly and Company (the 'Company') held its annual meeting of shareholders on May 3, 2021 (the '2021 Annual Meeting'). Voting results for each matter submitted to a vote at the 2021 Annual Meeting are provided below.

a) The five nominees for director were elected to serve three-year terms ending at the Company's annual meeting of shareholders in 2024, as follows:

Nominee For Against Abstain Broker Nonvote
Katherine Baicker, Ph.D. 786,556,365 3,971,888 683,224 78,905,324
J. Erik Fyrwald 735,805,887 54,570,383 835,207 78,905,324
Jamere Jackson 699,430,362 90,868,049 913,066 78,905,324
Gabrielle Sulzberger 784,273,387 6,013,712 924,378 78,905,324
Jackson P. Tai 614,200,469 168,883,624 8,127,384 78,905,324

b) By the following vote, the shareholders approved, on an advisory basis, the compensation paid to the Company's named executive officers:

For: 755,296,772
Against: 34,051,860
Abstain: 1,862,845
Broker Nonvote: 78,905,324

c) The appointment of Ernst & Young as the Company's independent auditor for 2021 was ratified by the following shareholder vote:

For: 835,119,026
Against: 34,286,470
Abstain: 711,305

d) The proposal to amend the Company's Articles of Incorporation to eliminate the classified board structure did not receive the required vote of 80% of outstanding shares. The shareholders voted as follows:

For: 672,397,991
Against: 117,428,685
Abstain: 1,384,801
Broker Nonvote: 78,905,324



e) The proposal to amend the Company's Articles of Incorporation to eliminate supermajority voting provisions did not receive the required vote of 80% of outstanding shares. The shareholders voted as follows:

For: 671,655,729
Against: 118,200,383
Abstain: 1,355,365
Broker Nonvote: 78,905,324

f) By the following vote, a shareholder proposal requesting to disclose direct and indirect lobbying activities and expenditures was not approved:

For: 380,312,826
Against: 408,488,220
Abstain: 2,410,431
Broker Nonvote: 78,905,324

g) By the following vote, a shareholder proposal requesting to amend the bylaws to require an independent board chair was not approved:

For: 286,294,523
Against: 503,034,078
Abstain: 1,882,876
Broker Nonvote: 78,905,324

h) By the following vote, a shareholder proposal requesting the implementation of a bonus deferral policy was not approved:

For: 246,751,698
Against: 542,574,049
Abstain: 1,885,730
Broker Nonvote: 78,905,324

i) By the following vote, a shareholder proposal requesting to disclose clawbacks on executive incentive compensation due to misconduct was not approved:

For: 322,735,091
Against: 466,847,278
Abstain: 1,629,108
Broker Nonvote: 78,905,324

As of February 22, 2021, the record date of the 2021 Annual Meeting, 958,992,159 shares of common stock were issued and outstanding.




Disclaimer

Eli Lilly and Company published this content on 05 May 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 05 May 2021 11:00:05 UTC.


ę Publicnow 2021
All news about ELI LILLY AND COMPANY
09:06aELI LILLY ANDá : JPMorgan Adjusts Price Target on Eli Lilly to $260 From $240, M..
MT
07:59aELI LILLY ANDá : to Compare Migraine Drugs Emgality, Nurtec ODT in Phase 4 Study
MT
06/14ELI LILLY ANDá : Significant Insider Selling Continues at Eli Lilly (LLY)
MT
06/14ELI LILLY ANDá : Lilly to Participate in Guggenheim Biopharma Strategy Series
PR
06/14ELI LILLY ANDá : Bernstein Adjusts Price Target on Eli Lilly to $250 From $205, ..
MT
06/14ELI LILLY ANDá : Goldman Sachs Adjusts Eli Lilly's Price Target to $270 From $25..
MT
06/14Fiserv Appoints Wafaa Mamilli to Board of Directors
AQ
06/11ELI LILLY ANDá : Significant Insider Selling in Shares of Eli Lilly (LLY) Contin..
MT
06/11INSIDER TRENDS : Insider Sales Continue 90-Day Trend at Eli Lilly
MT
06/11ELI LILLY ANDá : Thinking about trading options or stock in Crispr Therapeutics,..
PR
More news
Financials (USD)
Sales 2021 27 273 M - -
Net income 2021 6 537 M - -
Net Debt 2021 11 213 M - -
P/E ratio 2021 31,1x
Yield 2021 1,47%
Capitalization 206 B 206 B -
EV / Sales 2021 7,95x
EV / Sales 2022 7,73x
Nbr of Employees 35 000
Free-Float 99,8%
Chart ELI LILLY AND COMPANY
Duration : Period :
Eli Lilly and Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ELI LILLY AND COMPANY
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 222,09 $
Last Close Price 226,10 $
Spread / Highest target 19,4%
Spread / Average Target -1,77%
Spread / Lowest Target -22,6%
EPS Revisions
Managers and Directors
NameTitle
David A. Ricks Chairman, President & Chief Executive Officer
Anat Ashkenazi Chief Financial Officer & Senior Vice President
Timothy J. Garnett Chief Medical Officer & VP-Global Medical
Daniel M. Skovronsky Chief Scientific Officer & Senior Vice President
Diogo Rau Senior VP, Chief Information & Digital Officer
Sector and Competitors
1st jan.Capitalization (M$)
ELI LILLY AND COMPANY33.91%205 531
JOHNSON & JOHNSON5.08%435 485
ROCHE HOLDING AG10.58%328 513
PFIZER, INC.7.66%221 837
NOVARTIS AG0.23%209 350
ABBVIE INC.7.70%203 822